Avidity Biosciences Inc [NASDAQ: RNA] traded at a high on 2025-09-18, posting a 4.37 gain after which it closed the day’ session at $41.81.
The results of the trading session contributed to over 4216775 shares changing hands. Over the past one week, the price volatility of Avidity Biosciences Inc stands at 7.40% while the volatility over the past one month is 5.99%.
The market cap for RNA stock reached $6.10 billion, with 120.78 million shares outstanding. Compared to the average trading volume of 3.13M shares, RNA reached a trading volume of 4216775 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Avidity Biosciences Inc [RNA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RNA shares is $68.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RNA stock is a recommendation set at 1.11. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Roth Capital have made an estimate for Avidity Biosciences Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 17, 2025. While these analysts kept the previous recommendation, Goldman raised their target price to Buy. The new note on the price target was released on July 10, 2025, representing the official price target for Avidity Biosciences Inc stock. Previously, the target price had yet another raise to $50, while Bernstein analysts kept a Outperform rating on RNA stock.
The Price to Book ratio for the last quarter was 4.23, with the Price to Cash per share for the same quarter was set at 8.11.
How has RNA stock performed recently?
Avidity Biosciences Inc [RNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.88. With this latest performance, RNA shares dropped by -5.02% in over the last four-week period, additionally plugging by 31.81% over the last 6 months – not to mention a rise of 43.78% in the past year of trading.
Avidity Biosciences Inc [RNA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Avidity Biosciences Inc [RNA] shares currently have an operating margin of -4863.30% and a Gross Margin at 71.60%. Avidity Biosciences Inc’s Net Margin is presently recorded at -4247.77%.
Avidity Biosciences Inc (RNA) Capital Structure & Debt Analysis
According to recent financial data for Avidity Biosciences Inc. ( RNA), the Return on Equity (ROE) stands at -37.76%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -33.56%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Avidity Biosciences Inc’s Return on Invested Capital (ROIC) is -38.17%, showcasing its effectiveness in deploying capital for earnings.
Avidity Biosciences Inc (RNA) Efficiency & Liquidity Metrics
Based on Avidity Biosciences Inc’s (RNA) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Avidity Biosciences Inc (RNA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Avidity Biosciences Inc. (RNA) effectively leverages its workforce, generating an average of -$1165575.45 per employee. The company’s liquidity position is robust, with a Current Ratio of 9.26% and a Quick Ratio of 9.26%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Avidity Biosciences Inc [RNA]
With the latest financial reports released by the company, Avidity Biosciences Inc posted -0.65/share EPS, while the average EPS was predicted by analysts to be reported at -0.72/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.07. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Avidity Biosciences Inc go to -7.86%.
Insider trade positions for Avidity Biosciences Inc [RNA]
There are presently around $101.77%, or 106.60%% of RNA stock, in the hands of institutional investors. The top three institutional holders of RNA stocks are: FMR LLC with ownership of 16.16 million shares, which is approximately 15.1121%. PRICE T ROWE ASSOCIATES INC /MD/, holding 10.92 million shares of the stock with an approximate value of $$445.94 million in RNA stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $$359.76 million in RNA stock with ownership which is approximately 8.2362%.
